bupropion and Cardiovascular Stroke

bupropion has been researched along with Cardiovascular Stroke in 18 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Research

Studies (18)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Composite Major Adverse Cardiovascular Events (MACE)

"All clinical end points were adjudicated by members of the Endpoints Evaluation Committee who were blinded to treatment assignment.~Composite MACE (death, myocardial infarction, unstable angina)" (NCT00689611)
Timeframe: 12 months

Smoking Abstinence

"The primary end point was 7-day point prevalence smoking abstinence at 12 months. Smoking cessation was defined as self-reported abstinence in the week before the 12-month clinic visit and a measurement of exhaled carbon monoxide less than 11 ppm.~The primary end point was analyzed on an intention-to-treat (ITT) basis. Our ITT analysis assumed that those who withdrew consent or were lost to follow-up had returned to smoking at their baseline rates. This assumption is common in smoking cessation trials." (NCT00689611)
Timeframe: 12 months

Percentage of Participants With a Confirmed Occurrence of Cardiovascular Death (Including Fatal Myocardial Infarction, Fatal Stroke)

Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up

Percentage of Participants With a Confirmed Occurrence of Cardiovascular Death, Nonfatal Myocardial Infarction, Nonfatal Stroke, or Nonfatal Unstable Angina Requiring Hospitalization

Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up

Percentage of Participants With a Confirmed Occurrence of Major Adverse Cardiovascular Event (MACE)

The primary endpoint is the time from randomization to the first confirmed occurrence of any event within the primary MACE composite (defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). Due to early termination of the study, pre-planned 50% interim analysis is considered the primary analysis for outcome measures. The pre-planned 50% interim analysis was conducted when 50% of the total planned MACE were observed. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up

Percentage of Participants With a Confirmed Occurrence of Myocardial Infarction (Nonfatal or Fatal)

Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up

Percentage of Participants With a Confirmed Occurrence of Stroke (Nonfatal or Fatal)

Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up

Interpersonal Reactivity Index (IRI)

This is a 14-item scale that measures empathy. The scoring scale ranges from 0, does not describe me well, to 4, describes me very well. The score values range from 0-56, where high values represent higher levels of empathy and lower values represent lower levels of empathy. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Medical Outcomes Study - Specific Adherence Scale (MOS- SAS)

This is a 3-item scale that measures health behaviors. The scoring scale ranges from 1, none of the time, to 6, all of the time. The scoring values range from 3-18, where higher values represent good health behavior and lower values represent poor health behavior. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Patient Health Questionnaire-9 (PHQ-9)

This is a 9-item scale that measures depression. The scoring scale ranges from 0, not at all, to 3, nearly every day. The scoring values range from 0-18, where high values represent higher levels of depression and lower values represent lower levels of depression. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Patient Reported Outcome Measurement Information System-Physical Function (PROMIS-29-PF)

This is a 4-item scale that measures and evaluates physical health. The scoring scale ranges from 5, without any difficulty, to 1, unable to do. The scoring values range from 4-20, where high values represent good physical function and low values represent poor physical function. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Perceived Stress Scale-4 (PSS-4)

This is a 4-item scale that measures stress. The scoring scale ranges from 0,never, to 4, very often. The scale values range from 0-16 with higher values representing higher levels of individual stress and lower values representing lower levels of individual stress. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Positive Affect Negative Affect Schedule (PANAS)

This is a 20-question scale, composed of 2, 10-item scales that measure positive and negative affect. The scoring scale ranges from 1, very slightly or not at all, to 5, extremely. For this study, we will only use the positive affect sub-scale. The scale values for the positive affect sub-scale range from 10-50. Higher values on the positive affect scale represent higher levels of positive affect, whereas, lower values on the negative affect scale represent lower levels of positive affect. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Rumination Response Scale (RRS)

This is a 22-item scale that measures rumination. The scoring scale ranges from 1,almost never, to 4, almost always. The score values range from 22 to 88, where higher values represent higher levels of rumination and lower values represent lower levels of rumination. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Self-Other Four Immeasurables (SOFI) Scale

This is a 16-item scale that measures views toward the self and others. This measure consists of four sub-scales with four items each. The sub-scales measure positive views toward self, negative views toward self, positive views toward others, and negative views toward other. Only the positive-other sub-scale was used. The scoring scale ranges from 1, very slightly or not at all to 5, extremely, with sub-scale scores ranging from 4-20. Higher values represent higher levels of positive feelings toward others, and lower values represent lower levels of positive feelings toward others. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Short-Form-12 (SF-12)

This is a 12-item scale that measures health-related quality of life. The scoring scale from item 1 ranges from 1, excellent to 5, poor. The scoring scale for items 2 and 3 ranges from 1, limit you a lot to 3, not limit you at all. The scoring scale for questions 5-7 is represented by 1, yes or 2, no. The scoring scale for item 8 ranges from 1, not at all, to 5, extremely. The scoring scale for items 9-11 ranges from 1, all of the time, to 6, none of the time. The scoring scale for item 12 ranges from 1, all of the time to 5, none of the time. The total scoring values range from 12- 47, where higher values represent a higher quality of life and lower values represent a lower quality of life. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Five Factor Mindfulness Questionnaire- 15 Item (FFMQ-15)

This is a 15-item measure that measures mindfulness. This scale has five sub-scales: observing, describing, acting with awareness, accepting without judgment, and non-reactivity. The scoring scale ranges from 1, never or very rarely true to 5, very often or always true. Scale values range from 3-15 for each sub-scale, with higher values representing greater levels of individual mindfulness and lower values representing lowers levels of individual mindfulness. There is no total score for the measure; only individual sub-scales are reported. Data collection for this measurement is cross-sectional, and is collected during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Number of Participants Reporting Changes After ACS

This portion of the individual interview will focus on exploring changes experienced after an ACS, such as psychosocial changes and health behavior changes. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The identified themes are reported, and the criteria used to determine the outcome measure is the number of participants who endorsed each theme. (NCT03878160)
Timeframe: one 30-90-minute session

Number of Participants With Perspectives on Blood Spot Data Collection

This portion of the individual interview will focus on exploring ACS patients who had perspectives on participating in a remote dried blood spot procedure. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The criteria used to determine the outcome measure is the number of participants upon interview who reported any type of perspective on participating in a remote dried blood spot procedure (self-collection of dried blood spot via finger-prick). Please note that the number of perspectives reported for each theme can exceed the number of people per group because each participant reported multiple perspectives (e.g., both pros and cons of videoconferencing). (NCT03878160)
Timeframe: one 30-90-minute session

Number of Participants With Perspectives on MBCT

This portion of the individual interview will focus on exploring patients' perspectives toward an MBCT treatment approach. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The identified themes are reported, and the criteria used to determine the outcome measure is the number of participants who endorsed each theme. (NCT03878160)
Timeframe: one 30-90-minute session

Number of Participants With Perspectives on Videoconferencing

This portion of the individual interview will focus on exploring perspectives regarding videoconferencing intervention delivery. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. Identified themes are reported, and the criteria used to determine the outcome measure is the number of participants upon interview who reported expressed each theme. (NCT03878160)
Timeframe: one 30-90-minute session

7-Day Point Prevalence Smoking Abstinence

7-day point prevalence abstinence at week 12, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 12 weeks

7-Day Point Prevalence Smoking Abstinence

7-day point prevalence abstinence at week 24, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 24 weeks

7-Day Point Prevalence Smoking Abstinence

7-day point prevalence abstinence at week 4, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 4 weeks

7-Day Point Prevalence Smoking Abstinence

7-day point prevalence abstinence at week 52, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 52 weeks

Continuous Smoking Abstinence

Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 12. (NCT00794573)
Timeframe: 12 weeks

Continuous Smoking Abstinence

Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 24. (NCT00794573)
Timeframe: 24 weeks

Continuous Smoking Abstinence

Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 4. (NCT00794573)
Timeframe: 4 weeks

Continuous Smoking Abstinence

Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 52. (NCT00794573)
Timeframe: 52 weeks

Reduction in Daily Cigarette Consumption by 50% or Greater

(NCT00794573)
Timeframe: 12 weeks

Reduction in Daily Cigarette Consumption by 50% or Greater

(NCT00794573)
Timeframe: 24 weeks

Reduction in Daily Cigarette Consumption by 50% or Greater

(NCT00794573)
Timeframe: 4 weeks

Reduction in Daily Cigarette Consumption by 50% or Greater

(NCT00794573)
Timeframe: 52 weeks

Reviews

3 reviews available for bupropion and Cardiovascular Stroke

Trials

5 trials available for bupropion and Cardiovascular Stroke

Other Studies

10 other studies available for bupropion and Cardiovascular Stroke